REDEFINING THE RETINOID PATHWAY: UNLEASHING THE POWER OF FIRST-IN-CLASS ORAL INHIBITORS
KayoThera specializes in pioneering a novel class of safe oral antagonists that are the first of their kind to target retinoid signaling. Previously considered “undruggable,” the retinoid pathway has posed challenges to drug development for nearly three decades. Past clinical experience with retinoid pathway activators has revealed two consistent findings among thousands of patients: adverse outcomes in solid cancers and a range of cardiometabolic effects, from hyperlipidemias to insulin resistance.
In response, KayoThera has developed a comprehensive pipeline of drugs focused on inhibiting retinoid signaling based on new biological insights to the pathway. The lead program in oncology aims to target retinoid synthesis in immune cells, while the cardiometabolic program concentrates on inhibiting retinoids in the pancreas, muscle, and fat-storing tissues. By pursuing this innovative approach, KayoThera aims to address critical medical needs and potentially revolutionize the treatment landscape in both oncology and cardiometabolic diseases.
LATEST NEWS
Kayothera selected as finalist in BIO’s Start-up Stadium
Kayothera will be presenting on their novel immune oncology pipeline during the week of June 10 at BIO's annual meeting. Pitches for the Startup Stadium will go live on Thursday followed by voting.
KayoThera to graduate from Endless Frontier Labs Accelerator
KayoThera has taken part in the NYU Stern Business School Endless Frontier Labs accelerator program since October 2020 to refine the business plan and expand the company trajectory and growth initiatives. This accelerator was exceptionally valuable to the development...
KayoThera founders publish Nature Cancer review on new therapeutic strategies to treat incurable cancers
Announcing a new review on emerging strategies to treat advanced cancers published in Nature Cancer.
KayoThera founders announce discovery of a new organelle driving cancer metastasis
In the cover article of the March issue of Nature Cell Biology, Dr. Mark Esposito and Dr. Yibin Kang announce the discovery of a novel driver of breast and prostate cancer metastasis. This newly discovered organelle is driven by a relatively unknown protein named...
KayoThera will present at BioNJ’s 10th Annual Biopartnering conference
KayoThera will be presenting at this year's 10th Annual BioNJ Biopartnering Conference. Please join us Tuesday, October 6 & Wednesday, October 7, 2020.
KayoThera launches with Seed Funding Round from NJHF
Kayothera, an early-stage therapeutics company and Princeton University spinout, is working to give hope to some of the most vulnerable cancer patients. Now the company’s aspirations are being bolstered by significant seed funding received from the New Jersey Health...